Invizius is a spin-out based on world-class research carried out at the University of Edinburgh, Scotland, developing solutions to improve the treatment and prognosis for dialysis patients.

Despite significant improvements in the quality and efficacy of hemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications. With its proprietary H-Guard™ technology, Invizius is addressing the side effects of hemodialysis to help patients feel better, and suffer fewer cardiovascular complications.